Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)
Clinical Infectious Diseases2007Vol. 44(10), pp. 1289–1297
Citations Over TimeTop 1% of 2007 papers
Oliver A. Cornely, Johan Maertens, Mark Bresnik, Ramin Ebrahimi, Andrew J. Ullmann, Emilio Bouza, Claus Peter Heußel, O. Lortholary, C. Rieger, Angelika Boehme, M. Aoun, Heinz A. Horst, Anne Thiébaut, Markus Ruhnke, Dietmar Reichert, Nicola Vianelli, Stefan W. Krause, Eduardo Olavarría, Raoul Herbrecht, AmBiLoad Trial Study Group
Abstract
In highly immunocompromised patients, the effectiveness of 3 mg/kg of liposomal amphotericin B per day as first-line therapy for invasive aspergillosis is demonstrated, with a response rate of 50% and a 12-week survival rate of 72%. The regimen of 10 mg/kg per day demonstrated no additional benefit and higher rates of nephrotoxicity.
Related Papers
- → Colistin Dosing and Nephrotoxicity in a Large Community Teaching Hospital(2010)173 cited
- CNS-aspergillosis: are there new treatment options?(2003)
- → Calcium-channel blocking agents as therapy for amphotericin B nephrotoxicity(1992)5 cited
- → Case report: invasive aspergillosis successfully treated with voriconazole without recurrence during subsequent bone marrow transplantation(2003)2 cited
- [Experience with voriconazole in invasive aspergillosis].(2003)